guaifenesin Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Guaifenesin is an expectorant the action of which promotes or facilitates the removal of secretions from the respiratory tract. The precise mechanism of action of guaifenesin is not known; however, it is thought to act as an expectorant by increasing the volume and reducing the viscosity of secretions in the trachea and bronchi. In turn, this may increase the efficiency of the cough reflex and facilitate removal of the secretions. Guaifenesin is over-the-counter drug for the treatment of cough and common cold.   NCATS

Chemistry

  • SMILES: COC1=CC=CC=C1OCC(O)CO
  • InChIKey: HSRJKNPTNIJEKV-UHFFFAOYSA-N
  • Mol. Mass: 198.2158
  • ALogP: 0.43
  • ChEMBL Molecule:
    guaifenesin  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Over the Counter
  • Delivery Methods: Oral
  • Pro Drug: No

Drug Pricing (per unit)

United States

$0.0119 - $8.0680
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Combination drugs

( hydrocodone (hycodan), guaifenesin, pseudoephedrine (Benylin) )
|
( guaifenesin, pseudoephedrine (Benylin) )
|
( guaifenesin, dextromethorphan (delsym) )
|
( hydrocodone (hycodan), guaifenesin - other names: flowtuss, xtrelus )

Alternative names

amonidron | famel | franolyn chesty | gecolate | glycerin guaiacolate | glycerol guaiacolate | glyceryl guaiacolate | guaiacol glyceryl ether | guaifenesin | guaifenesine | guaiphenesin | guaiphenesine | humabid | hustosil | liqufruta | methphenoxydiol | mucinex | myocain | myocaine | myoscain | nirolex for chesty cough decongestant | robitussin | tixylix chesty cough

Organizations (36)

Research & Development (24)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (15)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (11)

Approved Indications (3)


 

Common Cold (approved 2002)

Cough (approved 2002)

Sinusitis

Experimental Indications - Clinical Trial Phases 1-4 (11)


 

Airway Management (Phase 3)

Bronchitis (Phase 4)

Common Cold (Phase 3)

Cough (Phase 3)

Healthy Volunteers (Phase 4)

HIV Infections (Phase 2)

Mucociliary Clearance (Phase 1)

Respiratory Tract Infections (Phase 4)

Rhinitis (Phase 2)

Sinusitis ()

Therapeutic Equivalency (Phase 1)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 36
  • # of Trial Organizations: 24

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue